Literature DB >> 10543561

Comparison of direct aortic and femoral cannulation for port-access cardiac operations.

D D Glower1, F M Clements, N P Debruijn, M Stafford-Smith, R D Davis, K P Landolfo, P K Smith.   

Abstract

BACKGROUND: Differences in outcome after direct aortic cannulation (AORT) in the chest versus standard femoral arterial cannulation (FEM) have not been defined for minimally invasive cardiac operations utilizing the port-access approach.
METHODS: A retrospective study was performed of 165 patients undergoing port-access cardiac mitral valve operation (n = 126) or coronary artery bypass grafting (n = 39). In 113 patients, FEM was used, while in 52 patients, AORT was accomplished through a port in the first intercostal space.
RESULTS: AORT eliminated endoaortic balloon clamp migration (0/36 [0%] vs. 17/95 [18%]), and groin wound or femoral arterial complications (0/52 [0%] vs. 11/113 [10%]) without changing procedure times (363+/-55 vs. 355+/-70 minutes). Complications attributable to AORT were injury to the right internal mammary artery and aortic cannulation site bleeding in 1 patient each.
CONCLUSIONS: Direct aortic cannulation is technically easy, allows use of an endoaortic clamp, and avoids aorto-iliac arterial disease, the groin incision, and possible femoral arterial injury associated with femoral arterial cannulation. Direct arterial cannulation should expand the pool of patients eligible for port-access operation, and may become the standard for port-access procedures.

Entities:  

Mesh:

Year:  1999        PMID: 10543561     DOI: 10.1016/s0003-4975(99)00950-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Utility of Ultrasonographic Assessment of Distal Femoral Arterial Flow during Minimally Invasive Valve Surgery.

Authors:  Mitsuharu Hosono; Hiroshi Yasumoto; Shintaro Kuwauchi; Yoshino Mitsunaga; Shinya Kanemoto; Naoki Minato; Kohei Kawazoe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-06-07       Impact factor: 1.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.